White Paper

Which of the 6 Top Quality Errors Is Your Pharma Company Making?

Overcoming Pharma’s Top 6 Quality and Compliance Oversights
What's Included:
  • How a smarter approach to quality saves leading pharma companies an average of $284,813 annually.
  • Why training issues are at the root of most Form 483 observations and what you can do to avoid them.
  • Ways modern digital tools accelerate compliance in pharma manufacturing and make it less expensive.
About This Asset

Quality and compliance mistakes can be costly or even disastrous. So why do pharma companies still make them so often? This industry brief examines the six most common compliance oversights in pharma and shows steps you can take to avoid them. 

Download the supporting resources by filling out this form

Trusted By

Modernize Your Approach to Compliance


Better Performance Requires Better Tools

Automated processes and connected data are worth the price. But only when the value you gain is greater than your total investment. See how enterprise quality management systems (EQMS) help pharma companies achieve dramatic improvements.


Align With Regulators’ Risk Policies

The “as low as reasonably practicable” method for managing risk is no longer sufficient. The FDA expects you to take a smarter approach. Learn how advanced pharma quality management software can improve your capacity to track and trend risk data.


Extend Quality Across the Enterprise

It may seem impossible to establish a culture of quality that spans a large organization. But with the right pharma quality management system, you can make it a reality. Learn how to embed a quality mindset and unify compliance efforts across departments and contractors.

Don’t let tiny quality issues become giant compliance disasters.

Compliance oversights are avoidable with the right strategies and tools.

Get the Industry Brief
[ { "key": "fid#1", "value": ["Everything else"] } ]